Merck and Lupin collaborate to co-market Merck’s Pneumovax 23 Pneumococcal polysacharide vaccine for Indian market

New Drug Approvals

Merck has partnered with India based Lupin to co-market its pnemococcal vaccine in India. Lupin gets a non-exclusive license to market, promote and distribute Pneumovax under a different brand name in India. With patients suffering from respiratory disease like Asthma as candidates for pneumococcal vaccination,  Lupin which has a strong presence in this segment seems to be a right choice.
 The Pneumococcal vaccine is sold under the brand name Pneumovax 23 in the US…………….
read all at

Pneumococcal polysaccharide vaccine (PPSV) — the latest version is known asPneumovax 23 (PPV-23) — is the first pneumococcal vaccine, the first vaccine derived from a capsular polysaccharide, and an important landmark in medical history. The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of pneumococci by phagocytic cells. The pneumococcal polysaccharide vaccine is widely used in high-risk adults. As a result, there have been important reductions…

View original post 77 more words


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s